|
茵陈五苓散加减治疗非酒精性脂肪性肝病的Meta分析
|
Abstract:
目的:系统评价茵陈五苓散加减治疗非酒精性脂肪性肝病(Nonalcoholic fatty liver disease, NAFLD)的临床疗效。方法:计算机检索中国知网、重庆维普全文、万方数据知识服务平台、中国生物医学文献服务系统和Pub Med、The Cochrane Library、EMbase,收集茵陈五苓散加减治疗NAFLD的随机对照试验(randomized controlled trial, RCT),提取相关数据,用Cochrane对文献质量进行评价,用Rveman进行Meta分析。结果:纳入RCT文献9篇,共871例患者。Meta分析结果显示,治疗组用药有效率及改善肝功能、血脂异常方面优于对照组。结论:茵陈五苓散加减联合常规疗法治疗NAFLD效果优于单纯常规疗法。但本次纳入研究的文献数量、质量有限,使得该结论有待商榷,需更多高质量、大样本、多中心的RCT验证。
Objective: To evaluate the clinical efficacy of Yinchen Wuling powder in the treatment of Nonalcoholic fatty liver disease (NAFLD). Methods: China National Knowledge Infrastructure (CNKI), Chongqing VIP full text, Wanfang Data knowledge service platform, China Biomedical Literature Service System, Pub Med, The Cochrane Library, EMbase were searched by computer. Randomized controlled trials (RCT) of Yinchen Wuling powder in the treatment of NAFLD were collected, and the relevant data were extracted. Cochrane was used to evaluate the quality of the literature, and Rveman was used for meta-analysis. Results: Nine RCT articles were included, with a total of 871 patients. The results of meta-analysis showed that the effective rate and improvement of liver function and dyslipidemia in the treatment group were better than those in the control group. Conclusion: Yinchen Wuling powder combined with conventional therapy is better than conventional therapy in the treatment of NAFLD. However, due to the limited quantity and quality of the included studies, this conclusion is open to discussion, and more high-quality, large-sample and multicenter RCT verification is needed.
[1] | 赵红, 谢雯. 非酒精性脂肪性肝病的中西医结合治疗现状[J]. 中国临床医生杂志, 2020, 48(1): 16-18. |
[2] | 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版) [J]. 实用肝脏病杂志, 2018, 21(2): 177-186. |
[3] | 中华医学会内分泌学分会. 非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版) [J]. 临床肝胆病杂志, 2018, 34(10): 2103-2108. |
[4] | 孙沐炎. 五苓散临证思考[J]. 新中医, 2021, 53(11): 12-14. https://doi.org/10.13457/j.cnki.jncm.2021.11.003 |
[5] | 吴霞. 茵陈五苓散联合阿托伐他汀治疗非酒精性脂肪肝的效果分析[J]. 青海医药杂志, 2021, 51(11): 46-48. |
[6] | 程晓毅, 刘惠霞. 茵陈五苓散联合阿托伐他汀治疗非酒精性脂肪肝临床疗效及药物不良反应分析[J]. 贵州医药, 2020, 44(1): 106-107. |
[7] | 刘阳. 茵陈五苓散对非酒精性脂肪肝的临床价值分析[J]. 中国医药指南, 2019, 17(30): 222-223.
https://doi.org/10.15912/j.cnki.gocm.2019.30.187 |
[8] | 徐立, 符晶, 方芳, 等. 加味茵陈五苓散治疗湿热蕴结型非酒精性脂肪性肝病的疗效及对肠道菌群的影响[J]. 中国实验方剂学杂志, 2019, 25(12): 127-132. https://doi.org/10.13422/j.cnki.syfjx.201901232 |
[9] | 陈艺, 周伟泽, 李燕. 茵陈五苓散联合阿托伐他汀对非酒精性脂肪肝患者安全性与有效性分析[J]. 光明中医, 2018, 33(24): 3711-3713. |
[10] | 刘慕. 茵陈五苓散治疗非酒精性脂肪肝疗效观察[J]. 现代中西医结合杂志, 2016, 25(6): 636-638. |
[11] | 阳航. 茵陈五苓散治疗非酒精性脂肪肝的临床研究[J]. 中外医学研究, 2015, 13(5): 39-40.
https://doi.org/10.14033/j.cnki.cfmr.2015.05.018 |
[12] | 周黎, 叶丽春. 加味茵陈五苓散治疗痰瘀阻滞型非酒精性脂肪性肝炎38例[J]. 浙江中医杂志, 2014, 49(2): 106.
https://doi.org/10.13633/j.cnki.zjtcm.2014.02.017 |
[13] | 刘晓琳, 赵连皓. 茵陈五苓散治疗非酒精性脂肪肝50例[J]. 陕西中医, 2011, 32(5): 520-521. |
[14] | 倪润, 李朝先, 琚坚. 非酒精性脂肪性肝病治疗进展[J]. 胃肠病学和肝病学杂志, 2022, 31(2): 136-140. |
[15] | 党天谋, 李玉珍. 还原型谷胱甘肽配合藿朴夏苓汤加味治疗非酒精性脂肪肝疗效观察[J]. 河北医药, 2013, 35(17): 2690-2691. |
[16] | 赵瀚东, 杨帆, 詹丽. 非酒精性脂肪性肝病发病机制研究进展[J]. 解放军医学院学报, 2022,43(3): 366-371.
http://kns.cnki.net/kcms/detail/10.1117.R.20220106.1732.004.html |
[17] | 赵文霞, 张丽慧. 非酒精性脂肪性肝病应归属“肝癖”论[J]. 河南中医, 2015, 35(8): 1820-1822.
https://doi.org/10.16367/j.issn.1003-5028.2015.08.0766 |
[18] | 张声生, 李军祥. 非酒精性脂肪性肝病中医诊疗专家共识意见(2017) [J]. 临床肝胆病杂志, 2017, 33(12): 2270-2274. |
[19] | 蔡小蓉, 杨建云, 肖炳坤, 黄荣清. 茵陈五苓散的药理及临床研究进展[J]. 中国临床药理学杂志, 2017, 33(9): 857-860. https://doi.org/10.13699/j.cnki.1001-6821.2017.09.024 |
[20] | 王新芳, 胡晨旻, 赵真, 张志群. 茵陈五苓散对胆汁淤积幼龄大鼠肝功能保护作用[J]. 中国公共卫生, 2021, 37(10): 1521-1526. |
[21] | 田婷, 陈华, 冯亚龙, 等. 泽泻药理与毒理作用的研究进展[J]. 中药材, 2017, 37(11): 2103-2108. |
[22] | 游昕, 熊大国, 郭志斌, 商友剑. 茯苓多种化学成分及药理作用的研究进展[J]. 安徽农业科学, 2015, 43(2): 106-109. |
[23] | 王天媛, 张飞飞, 任跃英, 等. 猪苓化学成分及药理作用研究进展[J]. 上海中医药杂志, 2017, 51(4): 109-112. |
[24] | 欧海亚, 叶小鹏, 李舒, 等. 基于网络药理学的茵陈五苓散治疗非酒精性脂肪肝病的机制分析[J]. 世界科学技术–中医药现代化, 2020, 22(5): 1750-1759. |